| P2093 | author name string | Yuh-Shyan Tsai | |
| | Hsiao-Yen Hsieh | |
| | Yeong-Chin Jou | |
| | Syue-Yi Chen | |
| | Tzong-Shin Tzai | |
| | Hsin-Tzu Tsai | |
| P2860 | cites work | Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer | Q35051774 |
| | Urothelial tumorigenesis: a tale of divergent pathways | Q36234720 |
| | The mechanism of DAB2IP in chemoresistance of prostate cancer cells | Q36725756 |
| | European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update | Q37832571 |
| | Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. | Q37859970 |
| | EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update | Q37860472 |
| | Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation | Q39723961 |
| | Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. | Q40446210 |
| | EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival | Q47625784 |
| | Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder | Q80726109 |
| | Aberrant prothymosin-alpha expression in human bladder cancer | Q81765414 |
| | Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma | Q84399270 |
| | On Molecular Classification of Bladder Cancer: Out of One, Many | Q85657356 |
| | Global cancer statistics | Q22241238 |
| | The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2 | Q24292232 |
| | The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer | Q24293508 |
| | An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB | Q24299235 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | Negative regulation of DAB2IP by Akt and SCFFbw7 pathways | Q33917635 |
| | Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. | Q34123174 |
| | Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin | Q34123261 |
| | Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines | Q34160419 |
| | The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth | Q34227747 |
| | Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer | Q34409667 |
| | Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. | Q34472920 |
| | Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer | Q34540268 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 733-740 | |
| P577 | publication date | 2016-03-22 | |
| P1433 | published in | Virchows Archiv | Q19059548 |
| P1476 | title | Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival | |
| P478 | volume | 468 | |